Skip to main content

Table 2 Annual Percent Changes (APC), and corresponding 95% Confidence Intervals (CI), of selected cancers by sex according to age groups, during the period 1996-2010, Sétif Cancer Registry

From: Time trends of cancer incidence in Setif, Algeria, 1986–2010: an observational study

Cancer or group of cancers All Ages 15-44 years 45-64 years 65+ years
  APC 95% CI APC 95% CI APC 95% CI APC 95% CI
Men         
Nasopharynx -3.4* (-5.1;-1.6) -4.9* (-8.5;-1.1) -4.0* (-6.8;-1.1) -2.4 (-9.8;+5.6)
Stomach -1.1 (-2.7;+0.6) -7.0* (-12.0;-1.8) -2.0 (-5.9;+2.2) +2.7 (-0.6;+6.1)
Colon-rectum +5.4* (+3.4;+7.6) -0.8 (-4.7;+3.3) +3.7* (+0.5;+7.0) +11.1* (+6.5;+15.8)
Liver +8.9* (+0.9;+17.5) +3.6 (-13.8;+24.6) +1.6 (-7.8;+12.1) +9.6 (-0.4;+20.6)
Gallbladder +1.0 (-5.2;+7.6) -4.3 (-15.3;+8.0) -0.2 (-8.2;+8.5) +3.3 (-4.8;+12.1)
Larynx +1.0 (-4.8;+7.1) +4.7 (-5.9;+16.4) -4.8 (-10.8;+1.6) +5.1 (-0.9;+11.4)
Lung +1.8* (+0.0;+3.6) +4.7 (-3.8;+14.0) +0.7 (-1.6;+3.1) +2.8* (+0.3;+5.4)
Prostate +4.3* (+2.0;+6.8) +1.0 (-18.4;+25.0) +0.9 (-3.7;+5.8) +5.0* (+1.7;+8.5)
Kidney +4.3 (-1.1;+10.0) +0.6 (-14.8;+18.7) +2.0 (-5.5;+10.1) -0.6 (-10.6;+10.6)
Bladder +5.9* (+4.1;+7.7) +7.4 (-1.1;+16.5) +3.5* (+0.4;+6.6) +8.0* (+4.7;+11.5)
Thyroid +3.2 (-3.6;+10.5) +0.1 (-7.6;+8.5) -0.2 (-9.1;+9.6) +2.6 (-7.2;+13.5)
Hodgkin lymphoma -0.6 (-7.8;+7.2) +1.2 (-6.6;+9.6) -1.9 (-11.1;+8.4) +5.4 (-8.0;+20.8)
Non Hodgkin lymphomas +0.8 (-3.3;+5.0) +2.3 (-2.8;+7.7) -1.8 (-8.4;+5.4) +4.4 (-2.7;+11.9)
Leukaemias +6.7 (-0.4;+14.2) +13.7* (+6.8;+21.0) +3.0 (-3.0;+9.4) +6.0 (-4.2;+17.2)
Unspecified and ill-defined cancers +0.5 (-4.2;+5.5) -0.6 (-9.1;+8.6) -1.1 (-6.5;+4.6) +4.4 (-1.7;+10.9)
All cancers but skin +2.5* (+1.6;+3.4) +1.5 (-0.4;+3.4) +0.9 (-0.4;+2.2) +5.1* (+3.8;+6.4)
Women         
Nasopharynx +2.5 (-1.6;+6.7) -0.7 (-6.1;+4.9) +5.5 (-1.6;+13.1) +0.0 (-6.7;+7.1)
Stomach +0.6 (-1.7;+2.9) -6.6* (-12.4;-0.4) +0.3 (-4.5;+5.4) +3.3 (-1.8;+8.6)
Colon-rectum +4.5* (+1.6;+7.4) -2.1 (-6.3;+2.3) +5.3* (+1.4;+9.3) +7.5* (+3.8;+11.3)
Liver +5.4* (+0.2;+10.8) +6.6 (-6.0;+20.8) +5.3 (-2.5;+13.8) +3.1 (-4.0;+10.8)
Gallbladder -3.2* (-5.8;-0.5) -8.7* (-14.5;-2.5) -2.8 (-5.8;+0.4) -2.1 (-6.6;+2.7)
Larynx +13.8* (+0.6;+28.7) +22.8 (-1.3;+52.9) +6.7 (-7.7;+23.3) +5.4 (-9.9;+23.2)
Lung +10.0* (+5.9;+14.2) +6.2 (-0.8;+13.6) +10.4* (+3.2;+18.1) +7.8* (+2.8;+13.1)
Breast +8.2* (+5.7;+10.7) +9.7* (+5.8;+13.7) +7.3* (+4.8;+9.9) +6.9* (+1.9;+12.2)
Cervix uteri -4.2* (-6.6;-1.7) -1.8 (-5.7;+2.3) -5.9* (-9.4;-2.3) -0.6 (-4.5;+3.4)
Ovary -2.1 (-6.7;+2.8) -0.0 (-6.1;+6.4) -7.5* (-11.5;-3.3) +0.8 (-5.1;+6.9)
Kidney -3.4 (-11.1;+4.9) +0.1 (-12.7;+14.7) -0.9 (-6.7;+5.2) +5.1 (-9.4;+22.1)
Bladder -4.4 (-15.4;+8.0) +0.1 (-21.8;+28.1) -10.4 (-26.3;+9.0) +4.0 (-5.2;+14.1)
Thyroid +5.3* (+2.8;+7.9) +9.8* (+5.6;+14.2) +5.0* (+1.8;+8.4) -0.8 (-5.3;+3.8)
Hodgkin lymphoma +4.7 (-1.3;+11.1) +3.2 (-1.6;+8.3) -1.2 (-9.3;+7.6) +23.9 (-4.1;+59.9)
Non Hodgkin lymphomas +2.9 (-1.0;+6.9) +6.3* (+0.9;+12.0) +4.1 (-1.1;+9.6) -2.1 (-8.1;+4.3)
Leukaemias +3.1 (-3.9;+10.6) +11.2* (+2.9;+20.1) -0.1 (-7.4;+7.8) +3.6 (-5.3;+13.4)
Unspecified and ill-defined cancers -0.4 (-5.9;+5.4) -5.4 (-11.0;+0.6) -3.2 (-9.1;+3.0) +4.6 (-2.8;+12.7)
All cancers but skin +3.7* (+2.6;+4.8) +5.2* (+3.1;+7.4) +2.8* (+1.6;+4.0) +4.4* (+2.5;+6.4)
  1. *p < 0.05.
\